Italia markets closed

Dow Jones
39.908,00
+349,89(+0,88%)
Nasdaq
16.742,39
+231,21(+1,40%)
Nikkei 225
38.385,73
+29,67(+0,08%)
EUR/USD
1,0885
+0,0064(+0,59%)
Bitcoin EUR
60.584,57
+4.026,21(+7,12%)
CMC Crypto 200
1.392,54
+124,59(+9,83%)

NVCR Sep 2024 17.500 call

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

5,47

+0,67

(+13,96%)

In data: 11:13AM EDT. Mercato aperto.

GlobeNewswire
Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with no added systemic toxicities Tumor Treating Fields therapy together with immune checkpoint inhibitors resulted in an unprecedented 8-month improvement in median overall survival LUNAR is the first phase 3 clinical trial in more than seven years to show a significant extension in overall survival in